MX375261B - Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca. - Google Patents

Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.

Info

Publication number
MX375261B
MX375261B MX2015012886A MX2015012886A MX375261B MX 375261 B MX375261 B MX 375261B MX 2015012886 A MX2015012886 A MX 2015012886A MX 2015012886 A MX2015012886 A MX 2015012886A MX 375261 B MX375261 B MX 375261B
Authority
MX
Mexico
Prior art keywords
sub
fibrosis
treatment
aromatic compounds
substituted aromatic
Prior art date
Application number
MX2015012886A
Other languages
English (en)
Other versions
MX2015012886A (es
Inventor
Boulos Zacharie
Brigitte Grouix
François Sarra-Bournet
Jean-François Bienvenu
Lilianne Geerts
Lyne Gagnon
Martin Leduc
Pierre Laurin
Shaun Abbott
Valérie Perron
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2015012886A publication Critical patent/MX2015012886A/es
Publication of MX375261B publication Critical patent/MX375261B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos aromáticos sustituidos para uso en la prevención o tratamiento de varias enfermedades y afecciones fibráticas en sujetos, incluyendo fibrosis pulmonar, fibrosis hepática, fibrosis de la piel y fibrosis cardiaca, donde el compuesto tiene la siguiente fórmula (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde A es alquilo C5, alquilo C6, alquenilo C5, alquenilo C6, C(O)-(CH2)n-CH3 o CH(OH)-(CH2)n-CH3 en donde n es 3 o 4; R1 es H, OH o F'; R2 es H, OH, F' o CH2-OH; R3 es H, OH, F' o CH2Ph; R4 es H, OH o F'; Q es 1) (CH2)mC(O)OH en donde m es 1 o 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)-C(O)OH, 5) CF2- C(O)OH, o 6) C(O)-C(O)OH.
MX2015012886A 2013-03-15 2014-03-14 Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca. MX375261B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798427P 2013-03-15 2013-03-15
PCT/CA2014/000237 WO2014138907A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis

Publications (2)

Publication Number Publication Date
MX2015012886A MX2015012886A (es) 2016-04-04
MX375261B true MX375261B (es) 2025-03-06

Family

ID=51535670

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012886A MX375261B (es) 2013-03-15 2014-03-14 Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.

Country Status (25)

Country Link
US (3) US9884802B2 (es)
EP (1) EP2970088B1 (es)
JP (1) JP6381557B2 (es)
KR (1) KR102303493B1 (es)
CN (1) CN105143170B (es)
AR (1) AR095427A1 (es)
AU (1) AU2014231649C1 (es)
BR (1) BR112015023129A2 (es)
CA (1) CA2905633C (es)
CL (1) CL2015002725A1 (es)
DK (1) DK2970088T3 (es)
EA (1) EA031511B1 (es)
ES (1) ES2780825T3 (es)
IL (1) IL241164B (es)
MX (1) MX375261B (es)
MY (1) MY194727A (es)
NZ (1) NZ712745A (es)
PH (1) PH12015502012A1 (es)
PL (1) PL2970088T3 (es)
PT (1) PT2970088T (es)
SG (1) SG11201507274PA (es)
TW (2) TWI742541B (es)
UY (1) UY35401A (es)
WO (1) WO2014138907A1 (es)
ZA (1) ZA201507062B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CA2963354A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
TWI723967B (zh) * 2014-11-12 2021-04-11 英商邊緣生物科技有限公司 用於組織自修復及再生之經取代芳族化合物及醫藥組合物
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US10046007B2 (en) * 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
EP3710004A1 (en) * 2017-11-15 2020-09-23 Galapagos NV Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN112469406B (zh) * 2018-05-31 2024-05-17 财团法人峨山社会福祉财团 硬脂酸用于预防或治疗肺纤维化的用途
US11820834B2 (en) 2018-07-10 2023-11-21 Novmetapharma Co., Ltd. Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease
SG11202103011YA (en) 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
EP3890717A4 (en) * 2018-12-05 2022-08-24 Liminal Biosciences Limited USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME
US12480960B2 (en) 2019-01-11 2025-11-25 University Of Virginia Patent Foundation Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
KR102133151B1 (ko) 2019-03-28 2020-07-13 주식회사 노브메타파마 Chp(사이클로-히스프로)를 포함하는 복막 섬유증의 예방, 개선 또는 치료용 조성물
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
MX2023004137A (es) * 2020-10-06 2023-06-22 Pharmaceutique Ingenew Inc Compuestos aromaticos sustituidos y composiciones farmaceuticas de los mismos.
US12053467B2 (en) 2020-12-18 2024-08-06 NovMeta Pharma Co., Ltd. Method of treating fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
PT2427416E (pt) * 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
KR20120090011A (ko) 2009-05-04 2012-08-16 프로메틱 바이오사이언시즈 인코포레이티드 3-펜틸페닐아세트산의 염 및 이의 약학적 용도
EA035494B1 (ru) * 2010-10-27 2020-06-25 Прометик Фарма Смт Лимитед Способ и применение композиции для ингибирования миграции клеток опухоли и образования метастазов
CN102070433B (zh) * 2010-12-27 2013-03-27 桂林师范高等专科学校 芳香基乙酸类衍生物的制备方法
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
TWI723967B (zh) * 2014-11-12 2021-04-11 英商邊緣生物科技有限公司 用於組織自修復及再生之經取代芳族化合物及醫藥組合物

Also Published As

Publication number Publication date
PH12015502012A1 (en) 2016-01-11
EA201591774A1 (ru) 2015-12-30
PT2970088T (pt) 2020-03-27
HK1220439A1 (en) 2017-05-05
SG11201507274PA (en) 2015-10-29
AR095427A1 (es) 2015-10-14
CA2905633A1 (en) 2014-09-18
US10450258B2 (en) 2019-10-22
US20160023983A1 (en) 2016-01-28
AU2014231649B2 (en) 2018-01-04
WO2014138907A1 (en) 2014-09-18
JP2016510769A (ja) 2016-04-11
DK2970088T3 (da) 2020-03-30
KR102303493B1 (ko) 2021-09-16
EA031511B1 (ru) 2019-01-31
PL2970088T3 (pl) 2020-11-02
CA2905633C (en) 2021-12-28
ZA201507062B (en) 2017-04-26
US11267779B2 (en) 2022-03-08
MY194727A (en) 2022-12-15
TWI689489B (zh) 2020-04-01
KR20160040452A (ko) 2016-04-14
US20200017432A1 (en) 2020-01-16
BR112015023129A2 (pt) 2017-07-18
EP2970088A1 (en) 2016-01-20
CN105143170B (zh) 2019-11-08
AU2014231649C1 (en) 2018-08-23
EP2970088B1 (en) 2020-01-01
US9884802B2 (en) 2018-02-06
MX2015012886A (es) 2016-04-04
CL2015002725A1 (es) 2016-04-15
IL241164A0 (en) 2015-11-30
IL241164B (en) 2020-11-30
TW201441185A (zh) 2014-11-01
NZ712745A (en) 2020-06-26
CN105143170A (zh) 2015-12-09
EP2970088A4 (en) 2016-10-19
AU2014231649A1 (en) 2015-10-22
JP6381557B2 (ja) 2018-08-29
TW202045469A (zh) 2020-12-16
UY35401A (es) 2014-10-31
TWI742541B (zh) 2021-10-11
US20180134649A1 (en) 2018-05-17
ES2780825T3 (es) 2020-08-27

Similar Documents

Publication Publication Date Title
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
PE20151722A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
EA201591775A1 (ru) Замещенные ароматические соединения и связанный с ними способ лечения фиброза
EA033124B1 (ru) Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта
EA201100447A1 (ru) Органические соединения
HK1213251A1 (zh) 作为突变idh抑制剂的3-嘧啶-4-基-恶唑烷-2-酮化合物
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201591390A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
EA201000113A1 (ru) Пиразольные соединения
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
UA107753C2 (xx) ЗАМІЩЕНІ ІНГІБІТОРИ АЦЕТИЛ-СоА КАРБОКСИЛАЗИ
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
MX2020004255A (es) Compuesto de pirimidina como inhibidor de las janocinasas.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX376283B (es) Compuestos de imidazopiridazina.
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
AR092971A1 (es) Inhibidores de agrecanasa
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PROMETIC PHARMA SMT LIMITED

FG Grant or registration